Related Experiment Video
Updated: Jul 24, 2026
12:29
Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Antifungal prophylaxis and empiric therapy in neutropenic patients
1Department of Clinical Research and Development, Janssen Research Foundation, Beerse, Belgium.
Archives of Medical Research
|January 1, 1993
Abstract:
The present paper is a review of antifungal therapy in neutropenic patients with particular emphasis of itraconazole in fungal opportunistic infections.
Insights
This review covers antifungal therapy for neutropenic patients, focusing on itraconazole for opportunistic fungal infections. It highlights current treatment strategies and the role of itraconazole in managing these serious infections.
Area of Science:
- Mycology
- Pharmacology
- Hematology
Background:
- Neutropenic patients are highly susceptible to opportunistic fungal infections.
- Fungal infections pose a significant threat to immunocompromised individuals, including those with neutropenia.
- Antifungal therapy is crucial for managing these infections in high-risk patient populations.
Purpose of the Study:
- To review current antifungal therapies for neutropenic patients.
- To emphasize the role and efficacy of itraconazole in treating opportunistic fungal infections.
- To provide an overview of treatment strategies for fungal infections in this vulnerable group.
Main Methods:
- Literature review of antifungal agents.
- Focus on clinical studies and guidelines regarding itraconazole.
- Analysis of treatment outcomes in neutropenic patients.
Main Results:
- Itraconazole demonstrates efficacy against a range of opportunistic fungal pathogens.
- The review synthesizes data on itraconazole's use in various clinical scenarios.
- Current treatment guidelines are discussed in relation to itraconazole's place in therapy.
Conclusions:
- Antifungal therapy is essential for neutropenic patients.
- Itraconazole is a valuable therapeutic option for opportunistic fungal infections.
- Further research may refine the optimal use of itraconazole in this patient population.
Related Concept Videos
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...